Catalent falls after new short call from Glasshouse Research
Catalent Inc. (NYSE:CTLT) dropped 4.9% following a short report from Glasshouse Research.
Glasshouse sees "material headwinds" for the pharmaceutical contract manufacturer going forward, leading the firm to give CTLT a "strong sell" recommendation.
Catalent (CTLT) didn't immediately return a Seeking Alpha email request for comment.
Catalent (CTLT) short interest is 2%.
Catalent shares jumped 13% on Nov. 28 after Barclays noted that the FDA cleared both Form 483 observations related to the company’s Belgium and Bloomington facilities, removing a key overhang on shares.
